Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819234 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT00819234 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 274 participants.
The verdict
NCT00819234, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, administered as separate subcutaneous (SC) injections, in obese and overweight subjects.
Interventions
- DRUG Placebo
- DRUG Pramlintide and Metreleptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819234
The ClinicalTrials.gov registry entry for NCT00819234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00819234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00819234 about?
NCT00819234 is a clinical study titled "Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin". Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, admi...
What is the current status of trial NCT00819234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2008-11. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00819234?
The interventions under investigation include: Placebo (DRUG), Pramlintide and Metreleptin (DRUG).
Who is sponsoring clinical trial NCT00819234?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.